The target 50–75% reduction of Aβ in the ongoing generally preventative/early AD trials of BACE1 inhibitor drug candidates (Table 4) contrasts to an approximated 20–40% protective reduction resulting from the A673T mutation [15,104,105,107]. Here, BACE1 is linked to Alzheimer disease.